Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760

Watchlist Manager
Shenzhen Mindray Bio-Medical Electronics Co Ltd Logo
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Watchlist
Price: 256.55 CNY 0.62% Market Closed
Market Cap: 311.1B CNY
Have any thoughts about
Shenzhen Mindray Bio-Medical Electronics Co Ltd?
Write Note

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Total Current Liabilities
ÂĄ12.9B
CAGR 3-Years
18%
CAGR 5-Years
21%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Total Current Liabilities
ÂĄ588.2m
CAGR 3-Years
75%
CAGR 5-Years
65%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Total Current Liabilities
ÂĄ2.9B
CAGR 3-Years
11%
CAGR 5-Years
23%
CAGR 10-Years
22%
J
Jafron Biomedical Co Ltd
SZSE:300529
Total Current Liabilities
ÂĄ1B
CAGR 3-Years
52%
CAGR 5-Years
31%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Total Current Liabilities
ÂĄ3.4B
CAGR 3-Years
0%
CAGR 5-Years
-6%
CAGR 10-Years
30%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Total Current Liabilities
ÂĄ5.8B
CAGR 3-Years
7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Mindray Bio-Medical Electronics Co Ltd
Glance View

Market Cap
311.1B CNY
Industry
Health Care

In the bustling city of Shenzhen, China, a thriving enterprise known as Shenzhen Mindray Bio-Medical Electronics Co., Ltd, has cemented its place within the global medical devices market. Born in 1991 amid the backdrop of China’s rapid economic expansion, Mindray embarked on an ambitious journey to revolutionize healthcare technology. The company operates across three main segments: patient monitoring and life support, in-vitro diagnostics, and medical imaging systems. Each category is crucial to the medical infrastructure, with patient monitoring systems tracking vital statistics in real-time, in-vitro diagnostics facilitating intricate lab testing, and medical imaging enabling precise internal examinations. The synergy among these segments allows Mindray to deliver comprehensive solutions that enhance both the quality and efficiency of healthcare systems worldwide. Mindray's business model is intrinsically tied to innovation and global distribution. The company continually invests in research and development, a strategic move that keeps it at the forefront of medical technology advancement. Its R&D centers — strategically located in China, the U.S., and Europe — work tirelessly to push the boundaries of medical technology and address the evolving needs of healthcare professionals. In tandem with its technological prowess, Mindray crafts a robust network of distribution that ensures its advanced devices reach hospitals and clinics across over 190 countries. This expansive market presence, coupled with competitive pricing strategies, has propelled the company to secure a formidable foothold in both emerging and developed economies, thereby transforming the accessibility and delivery of healthcare services on a global scale.

Intrinsic Value
372.4 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's Total Current Liabilities?
Total Current Liabilities
12.9B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Mindray Bio-Medical Electronics Co Ltd's Total Current Liabilities amounts to 12.9B CNY.

What is Shenzhen Mindray Bio-Medical Electronics Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
21%

Over the last year, the Total Current Liabilities growth was 27%. The average annual Total Current Liabilities growth rates for Shenzhen Mindray Bio-Medical Electronics Co Ltd have been 18% over the past three years , 21% over the past five years .

Back to Top